The Indian pharmaceutical industry is a global leader, ranking third in volume and 14th in value, with a market size of over $50 billion. Known as the “pharmacy of the world,” it supplies 20% of global generic medicines and is a key player in vaccines, exporting to over 200 countries. The industry is driven by strong R&D, cost-effective manufacturing, and a skilled workforce.
Companies like Sun Pharma, Dr. Reddy’s, Zydus Lifesciences, Cipla, and Lupin lead the sector. With increasing healthcare spending, rising chronic diseases, and export demand, India’s pharma industry has immense growth potential, especially in biotechnology, biosimilars, and innovative drug development.
India: The CDMO Capital of the World
India is known as the “CDMO (Contract Development and Manufacturing Organization) capital of the world,” dominating the global pharmaceutical outsourcing market. Indian companies provide end-to-end solutions, including drug development, manufacturing, and packaging, to major global pharma players. The country’s competitive pricing, skilled workforce, and regulatory expertise make it the preferred hub for outsourced pharmaceutical services.
Share Price
The shares of Zydus Lifescience Limited are currently trading at Rs. 997.4 up by 3.7% from its previous close of Rs. 961.45 as of January 07, 2025
Recent Updates
FDA Acceptance and Priority Review for CUTX-101
Sentynl Therapeutics (Wholly Owned Subsidiary of Zydus Lifesciences Ltd.) has announced that the U.S. FDA has accepted its New Drug Application (NDA) for CUTX-101 (Copper Histidinate) to treat Menkes disease. The FDA has also granted a six-month priority review for the drug, with a target decision date of June 30, 2025.
Potential First Treatment for Menkes Disease
If approved, CUTX-101 could become the first-ever FDA-approved treatment for Menkes disease, a rare and serious condition that affects infants. Menkes disease leads to problems with copper in the body, causing severe developmental and neurological issues. This approval offers hope for children suffering from the disease.
Zydus Enters Agreement with CVS Caremark
Zydus Lifesciences Ltd., a global healthcare company, has announced a strategic agreement with CVS Caremark, a CVS Health company. Under this agreement, Zydus will add its drugs Zituvio, Zituvimet, and Zituvimet XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets to the CVS Caremark template formulary, starting January 1, 2025. This partnership expands Zydus’ reach in the U.S. market and enhances its portfolio of medications available to patients.
Medications Added to the CVS Caremark Formular
Zituvio is a medication used for the treatment of type 2 diabetes, while Zituvimet and Zituvimet XR combine sitagliptin and metformin hydrochloride, which are also prescribed for managing type 2 diabetes. These medicines work together to help control blood sugar levels in adults with this condition. Adding these products to CVS Caremark’s formulary makes them more accessible to a larger patient base.
About the Company
Zydus Lifesciences Ltd. is a global healthcare company that focuses on innovation, research, and the development of high-quality medicines. With a strong presence in over 50 countries, the company offers a broad portfolio that includes branded and generic pharmaceuticals, biosimilars, and consumer healthcare products.
Zydus Lifesciences is dedicated to improving lives through cutting-edge healthcare solutions, and it invests heavily in research and development to drive innovation across various therapeutic areas. The company is committed to sustainability, quality, and making a positive impact on global health through its diverse range of medicines and wellness products.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
